Condition: Pulmonary Hypertension Due to Lung Diseases and Hypoxia · Sponsor: OrphAI Therapeutics
A Phase 2, Randomized, Double-Blind, Multi-Dose, Placebo-Controlled Study to Evaluate the Efficacy and Safety of LAM-001 in Adults with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD).
This description comes directly from the study's public registry record.
OrphAI Therapeutics · 2034332737 · aclinical@orphai-therapeutics.com
Always discuss trial participation with your own doctor first.
| University of Arizona | Tucson, Arizona, United States | Recruiting |
| Yale New Haven Hospital | New Haven, Connecticut, United States | Not Yet Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05798923